Monrovia CA – Earlier today Immunotech Laboratories, publicly traded under stock ticker IMMB announced the relocation of its Research and Development facility and provided updates on its clinical trials under way in Bulgaria, as well as background on its revolutionary approach to fighting cancer.
IMMB treats HIV / AIDS, Cancer and Hepatitis C patients using Immunotherapy, a revolutionary and growing style of treatments that has been receiving praise worldwide from experts like Mehmet Cengiz Oz (also known as ‘Dr. Oz’) and Dr. Otis Brawley from the American Cancer Society.
According to Wikipedia, Immunotherapy is:
… a medical term defined as the “treatment of disease by inducing, enhancing, or suppressing an immune response”. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
In simple terms, Immunotherapy causes your own body’s immune system to fight cancer.
Here’s IMMB President and Chief Science Officer Harry Zhabilov, and Dr. Oz and Dr. Otis Brawley on Immunotherapy:
IMMB Called Undervalued
IMMB has several patents for its Immunotherapy treatments and was recently evaluated by an Market Advisors, Inc who observed that the company is undervalued. It’s report “Fundamental Analysis for Today’s Investments,” issued February 19th, said that:
We have learned that pursuant to significantly positive results patient population targeting full blown AIDS patients, Immunotech has completed numerous clinical contracts with Mexican hospitals to initiate a complete effort of clinical trial protocol for its HIV/AIDS vaccine drug candidates. The successful outcome of these efforts will eventually provide the necessary regulatory means for its products registration approval in the Republic of Mexico and most likely open a venue to nearly all of Central and South America markets.
In our opinion, this company is hugely undervalued. The Company states it has assets over $10 million, while liabilities are less than $3 million. This equates to a $7 million net worth.
The full report can be read here: http://freepdfhosting.com/7bd113ff01.pdf
New R&D Facilities For Immunotech Laboratories
The new news from Immunotech Laboratories is that it’s relocating to new facilities. In a press release, the company said:
Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) today announced the company has relocated to a new Research & Development Lab facility in Monrovia, California.
The new facility incorporates more laboratory use of the actual facility than the combined Administrative space at the previous Pasadena location. The new location also is geographically more conveniently located for the Immunotech team.
In light of the recent announcements stating the HIV-AIDS and Hepatitis C clinical trials using the company’s patented “ITV-1” patented technology treatment by the Immunotech BG sister company, more clinical research and results testing is necessary. The new facility accommodates the additional lab space.
Utilizing a combination of the clinical tests and results being conducted in Bulgaria alongside the results analysis here in the USA at the new facility, Immunotech plans to submit all the results from the Bulgarian clinical trials for US Food & Drug Administration “FDA” approval on a pre IND meeting. Immunotech Laboratories plans to start working with IND Directions, LLC (http://inddirections.com)
Immunotech’s ultimate goal is to provide a worldwide FDA approved treatment for combating the HIV-AIDS virus with the intent of terminating the virus and restoring the immune system. The goal of this treatment is to achieve reduction of resistance of existing therapies on the market.
The clinical trials in Bulgaria (Referred to as EU) are scheduled to begin in May 2013 and end in October 2013, which will give Immunotech, the rights to receive approval for applications of the “IPF” Treatment. In this respect, Immunotech Laboratories BG has had a series of conversations with Mr. Vladimir Stoichev, the Deputy General Director from Sopharma Bulgaria, and the parties have had talks for the possible signing of a contract between Immunotech Laboratories BG and Sopharma, a leading pharmaceutical company in the European Union,
for joint production of IPF-ITV.
Stay tuned for more.
Disclosure: Zennie62.com and Zennie62Media, Inc. is not registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. This advertisement may contain several forward looking statements.
Bill Carroll